Biota, Inc.

Capretto Ehf.

Lipomedica Ehf.

Thordis Kristmundsdottir

Sveinbjorn Gizurarson

Halldor Thormar

Meir Haber

Helga Helgadottir

Skuli Skulason

Sigurdur Gudmundsson

A formulation to be used for administering a therapeutically effective amount of an antimicrobiologically active monoglyceride to a mammal including administering a pharmaceutical composition having a total volume of 1-5000 &#x3bc;L to a surface of the mammal such as the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface, the pharmaceutical composition including the therapeutically effective amount of the antimicrobiologically active monoglyceride dissolved or suspended in a volume of 1-5000 &#x3bc;L of an methoxypolyethylene glycol referred to as mPEG and polyoxyethylene glycol (PEG)-fatty acid mono- or diglyceride so that upon administration of the pharmaceutical composition to the surface the formulation expresses thermostability within the range from below zero degrees C. to above 35-40&#xb0; C. and thereby allows the antimicrobiologically active monoglyceride to exert its therapeutic effect.

Thermostable formulation of biologically active substances

The invention relates to an orally administrable mucoadhesive film which comprises one or more bioactive ingredients and, as a major film-forming polymer, at least one alginate which is capable of forming a low viscosity aqueous solution. Also provided is a process for preparing such films.

Orally administrable films and preparation thereof

The present invention relates to a method for counteracting infections caused by bacteria, fungi or virus such as Herpes Simplex Virus in skin or mucosal membranes, in particular genital membranes, of a mammal. The method comprises topically administering to the skin or mucosal membrane an effective amount of a formulation comprising a) at least one microbicidal lipid, b) at least one solubilizing agent which keeps the lipid dissolved in the formulation, and optionally 3) a gel-forming agent. The formulation used in the method may suitable be in the form of a hydrogel. The microbicidal lipid is preferably a C fatty acid, such as, e.g., lauric acid, or a derivative thereof, e.g., a monoglyceride such as capric acid 1-monoglyceride. The solubilizing agent may suitably be a glycofurol such as the commercially-available glycofurol 75. The invention also relates to novel pharmaceutical formulations for use in the method.

Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections

Growing community of inventors

Seltjarnarnes, Iceland

Thordis Kristmundsdottir